CL2020002223A1 - Anticuerpos anti-pd-l1 y usos de los mismos - Google Patents
Anticuerpos anti-pd-l1 y usos de los mismosInfo
- Publication number
- CL2020002223A1 CL2020002223A1 CL2020002223A CL2020002223A CL2020002223A1 CL 2020002223 A1 CL2020002223 A1 CL 2020002223A1 CL 2020002223 A CL2020002223 A CL 2020002223A CL 2020002223 A CL2020002223 A CL 2020002223A CL 2020002223 A1 CL2020002223 A1 CL 2020002223A1
- Authority
- CL
- Chile
- Prior art keywords
- seq
- antibodies
- fragments
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan anticuerpos anti-PD-1 o fragmentos de los mismos. Los anticuerpos o fragmentos de los mismos se unen específicamente al dominio C de inmunoglobulina de la proteína PD-L1. En varios ejemplos, los anticuerpo o fragmentos de los mismos incluyen una VH CDR1 de la SEQ ID NO: 1, una VH CDR2 de la SEQ ID NO: 116, una VH CDR3 de la SEQ ID NO: 117, una VL CDR1 de la SEQ ID NO: 4, una VL CDR2 de la SEQ ID NO: 5, y una VL CDR3 de la SEQ ID NO: 6, o variantes de cada uno de los mismos. Se proporcionan métodos de uso de los anticuerpos o fragmentos de los mismos para tratar y diagnosticar enfermedades tales como cáncer y enfermedades infecciosas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081079 | 2018-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002223A1 true CL2020002223A1 (es) | 2021-01-29 |
Family
ID=68060946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002223A CL2020002223A1 (es) | 2018-03-29 | 2020-08-28 | Anticuerpos anti-pd-l1 y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11220546B2 (es) |
| EP (1) | EP3589660A4 (es) |
| JP (1) | JP7124257B2 (es) |
| KR (2) | KR102475106B1 (es) |
| CN (1) | CN110891975B (es) |
| AU (1) | AU2019241339B2 (es) |
| BR (1) | BR112020019827A2 (es) |
| CA (1) | CA3086434C (es) |
| CL (1) | CL2020002223A1 (es) |
| EA (1) | EA202091590A1 (es) |
| IL (1) | IL275734B (es) |
| MX (1) | MX2020007842A (es) |
| MY (1) | MY188237A (es) |
| PE (1) | PE20210377A1 (es) |
| PH (1) | PH12020551173A1 (es) |
| SG (1) | SG11202006008WA (es) |
| UA (1) | UA125918C2 (es) |
| WO (1) | WO2019185029A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126905C2 (uk) * | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Антитіло до pd-l1 та його застосування |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| CA3109999A1 (en) | 2018-08-21 | 2020-02-27 | Abl Bio Inc. | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| WO2021219092A1 (en) * | 2020-04-30 | 2021-11-04 | I-Mab Biopharma Co., Ltd. | Pharmaceutical compositionscontaining anti-cd47 antibodies |
| US20230287125A1 (en) * | 2020-07-28 | 2023-09-14 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting pd-l1 and tgf-beta |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| CN114316045B (zh) * | 2020-09-29 | 2024-07-12 | 英诺欧奇生物医药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| EP4276466A4 (en) * | 2021-01-08 | 2024-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTIBODY SPECIFICALLY BINDING WITH PD-L1 AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY |
| BR112023016706A2 (pt) * | 2021-02-19 | 2023-10-31 | Seoul Nat Univ R&Db Foundation | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo |
| CN115073599B (zh) * | 2021-03-16 | 2023-04-28 | 北京天广实生物技术股份有限公司 | 结合pd-l1的抗体及其用途 |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| WO2023186113A1 (zh) * | 2022-04-02 | 2023-10-05 | 和铂医药(上海)有限责任公司 | 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用 |
| WO2024104373A1 (en) * | 2022-11-15 | 2024-05-23 | I-Mab Biopharma Co., Ltd. | Anti-pd-l1 nanobodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2011043194A1 (en) | 2009-10-09 | 2011-04-14 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and method for manufacturing the same |
| CA2936244A1 (en) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| EP4141032B1 (en) * | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| UA126905C2 (uk) | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Антитіло до pd-l1 та його застосування |
| CN107488229B (zh) * | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| CN108777906B (zh) | 2018-06-25 | 2020-06-16 | 珠海惠尔益电子科技有限公司 | 一种双灯组变焦电路及头灯 |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
-
2019
- 2019-03-29 PE PE2020001301A patent/PE20210377A1/es unknown
- 2019-03-29 EA EA202091590A patent/EA202091590A1/ru unknown
- 2019-03-29 KR KR1020207032104A patent/KR102475106B1/ko active Active
- 2019-03-29 UA UAA202005634A patent/UA125918C2/uk unknown
- 2019-03-29 EP EP19769368.2A patent/EP3589660A4/en active Pending
- 2019-03-29 SG SG11202006008WA patent/SG11202006008WA/en unknown
- 2019-03-29 MX MX2020007842A patent/MX2020007842A/es unknown
- 2019-03-29 MY MYPI2020003980A patent/MY188237A/en unknown
- 2019-03-29 CA CA3086434A patent/CA3086434C/en active Active
- 2019-03-29 AU AU2019241339A patent/AU2019241339B2/en active Active
- 2019-03-29 WO PCT/CN2019/080458 patent/WO2019185029A1/en not_active Ceased
- 2019-03-29 KR KR1020197031498A patent/KR102177931B1/ko active Active
- 2019-03-29 JP JP2019553005A patent/JP7124257B2/ja active Active
- 2019-03-29 US US16/610,071 patent/US11220546B2/en active Active
- 2019-03-29 CN CN201980003429.7A patent/CN110891975B/zh active Active
- 2019-03-29 BR BR112020019827-7A patent/BR112020019827A2/pt unknown
-
2020
- 2020-06-29 IL IL275734A patent/IL275734B/en unknown
- 2020-08-02 PH PH12020551173A patent/PH12020551173A1/en unknown
- 2020-08-28 CL CL2020002223A patent/CL2020002223A1/es unknown
-
2021
- 2021-12-28 US US17/563,502 patent/US20220119531A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202006008WA (en) | 2020-07-29 |
| US20220119531A1 (en) | 2022-04-21 |
| UA125918C2 (uk) | 2022-07-06 |
| WO2019185029A1 (en) | 2019-10-03 |
| US20200157222A1 (en) | 2020-05-21 |
| KR102475106B1 (ko) | 2022-12-08 |
| BR112020019827A2 (pt) | 2021-01-05 |
| CN110891975B (zh) | 2023-11-10 |
| PE20210377A1 (es) | 2021-03-02 |
| US11220546B2 (en) | 2022-01-11 |
| AU2019241339B2 (en) | 2021-08-12 |
| CA3086434C (en) | 2024-01-09 |
| JP2020518233A (ja) | 2020-06-25 |
| AU2019241339A1 (en) | 2019-11-14 |
| CA3086434A1 (en) | 2019-10-03 |
| NZ758371A (en) | 2024-10-25 |
| IL275734A (en) | 2020-08-31 |
| JP7124257B2 (ja) | 2022-08-24 |
| MX2020007842A (es) | 2020-09-25 |
| EP3589660A1 (en) | 2020-01-08 |
| KR20190128716A (ko) | 2019-11-18 |
| IL275734B (en) | 2022-06-01 |
| PH12020551173A1 (en) | 2021-05-31 |
| KR20200130747A (ko) | 2020-11-19 |
| CN110891975A (zh) | 2020-03-17 |
| EP3589660A4 (en) | 2021-04-07 |
| EA202091590A1 (ru) | 2021-01-21 |
| MY188237A (en) | 2021-11-24 |
| KR102177931B1 (ko) | 2020-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002223A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| CL2019001756A1 (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PY1829572A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CO2018010547A2 (es) | Receptores quiméricos y métodos de uso de los mismos | |
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| IL299221A (en) | Cd3 binding antibodies | |
| PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| EA201691225A1 (ru) | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 |